Paper

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis

BMJ 1998; 316 doi: 10.1136/bmj.316.7125.95 (Published 10 January 1998)
Cite this as: BMJ 1998;316:95
  1. François P Sarasin (sarasin-francois{at}diogenes.hcuge.ch), senior registrar, department of internal medicinea,
  2. Henri Bounameaux, head, division of angiology and haemostasisa
  1. a Medical Clinics and the Division of Angiology and Haemostasis, Department of Internal Medicine, Hospital Cantonal, University of Geneva Medical School, Geneva, Switzerland
  1. Correspondence to: Dr F PSarasin Department of Internal Medicine, Hospital Cantonal, 24 rue Micheli du Crest, 1211 Geneva 14, Switzerland
  • Accepted 8 September 1997

Abstract

Objective: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended.

Design: A decision analysis Markov model (with data extracted form literature) representing the risks of developing symptomatic venous thromboembolism, the risks of major bleeding, and the efficacy of anticoagulant treatment.

Subjects: A hypothetical cohort of 1000 carriers of factor V Leiden recovering from a first episode of deep vein thrombosis in the lower limbs.

Main outcome measures: Risks and benefits of, firstly, stopping oral anticoagulation 3 months after first episode of thrombosis with reinitiation of treatment only after recurrent thrombosis and, secondly, extension of oral anticoagulation up to 1 to 5 years.

Results: Despite consistent biases in favour of extended oral anticoagulation, analysis revealed that among factor V carriers the number of major haemorrhages induced by oral anticoagulants would exceed that of clinical pulmonary emboli prevented over the entire range of duration of anticoagulation (1 to 5 years). On the other hand, the number of recurrent deep vein thrombi prevented would exceed that of iatrogenic major bleedings.

Conclusion: The lack of evidence of a net clinical benefit of prolonged oral anticoagulation, at least beyond 1 year, among patients recovering from acute deep vein thrombosis does not support the decision to promote widespread genetic screening programmes to detect the factor V mutation.

Key messages

  • Patients who carry the factor V Leiden mutation have a more than twice the risk of recurrence after a first episode of deep vein thrombosis

  • Before screening for the abnormality is advocated in all patients recovering from acute deep vein thrombosis, it should be determined whether carriers of the mutation would benefit from the diagnosis

  • The risks (major haemorrhage) of extended oral anticoagulation beyond the usually recommended 3 month period would exceed its benefits, in terms of clinical pulmonary emboli prevented

  • The decision to promote widespread screening programmes to detect factor V mutation should be questioned in the absence of clinical benefit provided by extended use of oral anticoagulants

Footnotes

  • Funding No external funding.

  • Conflict of interest None.

  • Contributors HB initiated the formulation of the primary hypothesis of the study, discussed core ideas, and participated in data collection and in writing the manuscript. FPS participated in the formulation of the primary hypothesis of the study, discussed core ideas, and designed and built the decision analysis model. He also collected the data from the literature, analysed and interpreted the results, and wrote the manuscript.

  • Accepted 8 September 1997

Rapid responses

THIS WEEK'S POLL

Read related article

See previous polls

BMJ most popular